LynxDx is working to commercialize a prostate cancer urine diagnostic assay that is able to confidently prevent many unnecessary prostate biopsies. The test, called the MyProstateScore (MPS), is performed in a regulatory-compliant commercial laboratory. To assist in the global response to the COVID-19 pandemic, LynxDx has worked aggressively to repurpose our clinical laboratory infrastructure to offer diagnostic COVID-19 testing.
LynxDx Address
333 Jackson Plaza Ann Arbor, MI United States
LynxDx Email
Past Companies
LynxDxVice President of Finance and Human Resources